WO2008045834A3 - Inhibiteurs de kinases - Google Patents

Inhibiteurs de kinases Download PDF

Info

Publication number
WO2008045834A3
WO2008045834A3 PCT/US2007/080710 US2007080710W WO2008045834A3 WO 2008045834 A3 WO2008045834 A3 WO 2008045834A3 US 2007080710 W US2007080710 W US 2007080710W WO 2008045834 A3 WO2008045834 A3 WO 2008045834A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
kinase inhibitors
methods
kinases
kits
Prior art date
Application number
PCT/US2007/080710
Other languages
English (en)
Other versions
WO2008045834A2 (fr
Inventor
Jason W Brown
Qing Dong
Bheema R Paraselli
Jeffrey Alan Stafford
Michael B Wallace
Original Assignee
Takeda San Diego Inc
Jason W Brown
Qing Dong
Bheema R Paraselli
Jeffrey Alan Stafford
Michael B Wallace
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/539,857 external-priority patent/US8119655B2/en
Application filed by Takeda San Diego Inc, Jason W Brown, Qing Dong, Bheema R Paraselli, Jeffrey Alan Stafford, Michael B Wallace filed Critical Takeda San Diego Inc
Priority to EP07868389A priority Critical patent/EP2081930A2/fr
Priority to JP2009532518A priority patent/JP2010505961A/ja
Priority to CA002666130A priority patent/CA2666130A1/fr
Publication of WO2008045834A2 publication Critical patent/WO2008045834A2/fr
Publication of WO2008045834A3 publication Critical patent/WO2008045834A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Abstract

L'invention concerne des composés, destinés à être utilisés avec des kinases, qui comprennent un composé sélectionné dans le groupe constitué de (I), les variables étant telles que définies dans la description. L'invention concerne également des compositions pharmaceutiques, des nécessaires et des articles manufacturés comprenant lesdits composés; des méthodes et des intermédiaires utiles pour la préparation des composés; ainsi que des méthodes d'utilisation desdits composés.
PCT/US2007/080710 2006-10-09 2007-10-08 Inhibiteurs de kinases WO2008045834A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07868389A EP2081930A2 (fr) 2006-10-09 2007-10-08 Inhibiteurs de kinases
JP2009532518A JP2010505961A (ja) 2006-10-09 2007-10-08 キナーゼ阻害剤
CA002666130A CA2666130A1 (fr) 2006-10-09 2007-10-08 Inhibiteurs de kinases

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/539,857 US8119655B2 (en) 2005-10-07 2006-10-09 Kinase inhibitors
US11/539,857 2006-10-09
USPCT/US2006/39667 2006-10-10
PCT/US2006/039667 WO2007044779A1 (fr) 2005-10-07 2006-10-10 Inhibiteurs de kinase
US91262507P 2007-04-18 2007-04-18
US60/912,625 2007-04-18

Publications (2)

Publication Number Publication Date
WO2008045834A2 WO2008045834A2 (fr) 2008-04-17
WO2008045834A3 true WO2008045834A3 (fr) 2008-07-24

Family

ID=40800472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080710 WO2008045834A2 (fr) 2006-10-09 2007-10-08 Inhibiteurs de kinases

Country Status (3)

Country Link
EP (1) EP2081930A2 (fr)
CA (1) CA2666130A1 (fr)
WO (1) WO2008045834A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2009129191A1 (fr) * 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Polymorphes de sel chlorhydrate de 5-(3-(éthylsulfonyl)phényl)-3,8-diméthyl-n-(1-méthylpipéridin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide et leurs procédés d'utilisation
WO2009129401A1 (fr) * 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Inhibiteurs de kinases
EP2297145A2 (fr) * 2008-04-16 2011-03-23 Takeda Pharmaceutical Company Limited Polymorphes de 5-(3-(éthylsulfonyl)phényl)-3,8-diméthyl-n-(1-méthylpipéridin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide et procédés d'utilisation associés
EP2706059A1 (fr) 2008-06-11 2014-03-12 Genentech, Inc. Diazacarbazoles et procédés d'utilisation
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN115353484A (zh) * 2022-07-05 2022-11-18 西北师范大学 一种4位氨基取代咔唑、二苯并[b，d]呋喃和芴衍生物的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1134221A1 (fr) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Bêta-carbolines substituées comme inhibiteurs de lkB kinase
EP1209158A1 (fr) * 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Bêta-carbolines subtituées
EP1367058A1 (fr) * 2002-05-31 2003-12-03 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de tetrahydropyrane
WO2005123672A2 (fr) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2006040451A2 (fr) * 2004-10-11 2006-04-20 Universite Claude Bernard Lyon I Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
WO2006131552A1 (fr) * 2005-06-09 2006-12-14 Boehringer Ingelheim International Gmbh Alpha-carbolines comme inhibiteurs de cdk-1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1134221A1 (fr) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Bêta-carbolines substituées comme inhibiteurs de lkB kinase
EP1209158A1 (fr) * 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Bêta-carbolines subtituées
EP1367058A1 (fr) * 2002-05-31 2003-12-03 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de tetrahydropyrane
WO2005123672A2 (fr) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2006040451A2 (fr) * 2004-10-11 2006-04-20 Universite Claude Bernard Lyon I Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
WO2006131552A1 (fr) * 2005-06-09 2006-12-14 Boehringer Ingelheim International Gmbh Alpha-carbolines comme inhibiteurs de cdk-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHATTI, INAYAT A. ET AL: "Pyrolysis of 1-substituted pyrazoles and chloroform at 550 .degree.C: formation of .alpha.-carboline from 1-benzylpyrazoles", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY , (24), 3581-3586 CODEN: JCPRB4; ISSN: 0300-922X, 1997, XP002417212 *
MEHTA LINA K ET AL: "THE ELIMINATION OF AN ALKOXY GROUP IN THE PHOTO-GRAEBE-ULLMANN CONVERSION OF 1-(2,5-DIALKOXYPHENYL)TRIAZOLOPYRIDINES INTO CARBOLINES, AND THE PREPARATION OF.ALPHA.-,.GAMMA.- AND.DELTA.-CARBOLINE QUINONES", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY. LETCHWORTH, GB, vol. 11, 1993, pages 1261 - 1267, XP009077814, ISSN: 0300-922X *

Also Published As

Publication number Publication date
CA2666130A1 (fr) 2008-04-17
WO2008045834A2 (fr) 2008-04-17
EP2081930A2 (fr) 2009-07-29

Similar Documents

Publication Publication Date Title
WO2007117995A3 (fr) Inhibiteurs de kinase
MY146989A (en) Kinase inhibitors
WO2006044687A3 (fr) Inhibiteurs de kinase
WO2009146034A3 (fr) Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
WO2008079814A3 (fr) Inhibiteurs de mapk/erk kinase
WO2007104034A3 (fr) Activateurs de la glucokinase
WO2008115890A3 (fr) Inhibiteurs de mapk/erk kinase
WO2008079787A8 (fr) Activateurs de glucokinase
WO2007028135A3 (fr) Composes a base d'imidazopyridine
WO2007061923A3 (fr) Activateurs de la glucokinase
WO2007075847A3 (fr) Activateurs de glucokinase
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008055236A3 (fr) Inhibiteurs de kinase mapk/erk
WO2008116107A3 (fr) Activateurs de glucokinase
WO2007143434A3 (fr) Activateurs de glucokinase
WO2008054956A3 (fr) Inhibiteurs de kinases
WO2010111626A3 (fr) Inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2006105127A3 (fr) Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2009140624A3 (fr) Activateurs de la glucokinase
WO2008012532A3 (fr) Composés chimiques 428
WO2010008847A3 (fr) Inhibiteurs de pi3k/m tor
MY150542A (en) Cmet inhibitors
WO2009146218A3 (fr) Composés comprenant un pharmacore anti-inflammatoire et procédés d'utilisation
WO2008045834A3 (fr) Inhibiteurs de kinases
WO2008039359A3 (fr) Inhibiteurs de pyrimidine kinase bicyclique

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2009532518

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2666130

Country of ref document: CA

Ref document number: 2007868389

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868389

Country of ref document: EP

Kind code of ref document: A2